Recent Advances in the Treatment of Alopecia Areata : Episode 5

Physician and Patient Communication for the Management of Alopecia Areata

April 3, 2023

Raj Chovatiya, MD, PhD
George Han, MD, PhD

Opinion

Video

Expert dermatologists discuss the importance of continued education for physicians treating patients with alopecia areata.

EP: 1.Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

EP: 2.JAK Inhibitor Baricitinib for Treatment of Alopecia Areata

EP: 3.Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata

EP: 4.Novel Mechanisms of Action for Treatment of Alopecia Areata

EP: 5.Physician and Patient Communication for the Management of Alopecia Areata

Related Videos

Potential JAK Inhibitor Combination Regimens in Dermatology

Therapies in Development for Hidradenitis Suppurativa

"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology

Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH

How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?

The JAK Inhibitor Safety Conversation

Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University

Secukinumab and Bimekizumab for Hidradenitis Suppurativa

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.